ISO 11608 Needle-based Injection Systems

ISO 11608 addresses discrete-dose injection systems

ISO 11608-1 applies to single-patient needle-based injection systems intended to deliver discrete volumes of medicinal product through a needle or soft cannula by intradermal, subcutaneous or intramuscular administration. Systems can be prefilled or user-filled and can use replaceable or non-replaceable containers.

The scope does not automatically include every product with a needle. Important exclusions include many continuous-delivery systems whose delivery rate is clinically specified, stand-alone prefilled syringes covered by ISO 11040-8, refillable containers intended for repeated refilling, dental systems and routes such as intravenous, intrathecal or intraocular administration.

Confirm the exact scope against the current standards. The main 2022 edition of Part 1 now has Amendment 1:2026, which should be considered in any new standards plan.

The parts divide requirements without dividing responsibility

Most products require Part 1 plus one or more additional parts. The manufacturer should also identify applicable standards outside the series—for risk management, usability, biocompatibility, software, electrical safety, sharps protection, primary containers, packaging, sterilisation and transport.

Part 3 also has Amendment 1:2026. Record the edition and amendment status used for every applicable part rather than citing only “ISO 11608”.

Define the drug–container–device system

Injection performance emerges from interacting elements. Medicinal-product viscosity, surface tension, particles, temperature and stability affect forces and delivery time. Container dimensions and stopper behaviour affect mechanism travel. Needle geometry and flow resistance affect pressure. User handling and tissue interaction influence whether the intended dose reaches the patient.

Use MTL-112 — Systems Engineering, Architecture and Interfaces to define boundaries and ownership across the complete delivery system.

Primary functions anchor the performance argument

The ISO 11608 series uses the concept of primary function for functions required to achieve delivery. Dose delivery—and the demonstrated accuracy of the delivered dose—is central, but the complete set depends on the product architecture and risk analysis.

• Identify functions required to prepare the system and make the fluid path ready.
• Define selection or control of the intended dose where the dose is variable.
• Specify initiation, needle or cannula placement, delivery and completion behaviour.
• Define prevention or indication of incomplete, unintended or repeated delivery.
• Identify protection against needle injury, contamination and inappropriate reuse.
• Define electronic or automated functions needed to achieve or confirm delivery.
• Set measurable limits and observable acceptance criteria for each function.
• Explain which failures can create unacceptable risk and how they are controlled.

Primary function and IEC 60601 essential performance are related but not interchangeable concepts. Use MTL-113 — Essential Performance and Safety Concepts to build a risk-based safety rationale where electrical medical-equipment requirements also apply.

Connect ISO 11608 with risk and usability engineering

Compliance testing does not replace product-specific risk management. Analyse overdose, underdose, delayed or missed dose, wrong dose, unintended delivery, leakage, occlusion, loss of sterility, needle injury, contamination, misuse, mechanical failure and misleading feedback across normal use and foreseeable fault conditions.

Use MTL-302 — ISO 14971 Risk Management for the risk framework and MTL-305 — IEC 62366-1 Usability Engineering for the safety-focused usability process.

Convert the intended therapy into design inputs

Requirements should describe what the complete system must achieve across its claimed operating range, shelf life and foreseeable use. Avoid copying test clauses into a specification without identifying the clinical and engineering rationale.

• Define nominal, minimum and maximum doses and any dose increments.
• Specify permissible delivered-volume or delivered-mass error across the dose range.
• Define delivery time, hold time, flow behaviour and completion indication.
• Set medicinal-product viscosity, temperature and other physical-property ranges.
• Define container, needle, accessory and device compatibility.
• Specify operating, storage, transport, humidity, orientation and pressure conditions.
• Define shelf life, in-use life, reuse cycles and battery or energy capability.
• Set activation, dose-setting, insertion, removal and other user-force requirements.
• Define sterility, fluid-path integrity, particulate, leakage and material requirements.
• Identify electronic, automated, connectivity and data functions that affect delivery.

Use MTL-103 — User Needs and Design Inputs to keep clinical intent, stakeholder needs and testable engineering requirements connected.

Dose accuracy is a system result

Dose accuracy cannot be assigned to the drive mechanism alone. It is influenced by container dimensions, stopper friction, needle and fluid-path resistance, dead volume, mechanism tolerances, medicinal-product properties, orientation, temperature, user technique and measurement uncertainty.

• Define whether dose is evaluated by volume, mass or another justified measure.
• Cover relevant minimum, intermediate and maximum dose settings.
• Use representative medicinal product or a justified substitute with controlled properties.
• Evaluate the combinations of container, needle, device and configuration placed on the market.
• Address beginning, middle and end of container or device life where performance can differ.
• Condition samples and test at relevant environmental and ageing states.
• Control priming, hold time, orientation, evaporation and residual droplets.
• Quantify measurement-system uncertainty and its effect on acceptance.
• Analyse individual results and distribution—not only an average.

A passing mean can hide unacceptable individual doses. The acceptance model, sample plan and treatment of invalid tests should be defined before data are examined.

Container and fluid path evidence must represent the final combination

ISO 11608-3 covers design verification of containers and integrated fluid paths used with systems under Part 1. The evidence should address the configured combination, including product-contact materials, closures, connections, lubrication and device forces.

The 2026 amendment to Part 3 should be included in the current applicability review. Pharmaceutical, device and supplier teams need shared specifications rather than disconnected acceptance documents.

Needle performance includes compatibility and injury prevention

ISO 11608-2 applies to single-use, double-ended sterile pen needles used with applicable non-integrated systems. Needles integrated into the container or fluid path fall under Part 3. Other needle types can be governed by different standards even when some ISO 11608 methods remain informative.

• Confirm attachment, fit, alignment and compatibility across claimed systems.
• Assess penetration, flow, blockage, leakage, breakage and pull-off or separation behaviour.
• Control needle dimensions, point geometry, lubrication, sterility and packaging.
• Consider shield removal, visibility, grip and the risk of incorrect attachment.
• Evaluate needle-stick prevention and sharps-protection functions where provided.
• Define resistance to reuse or inappropriate reactivation where relevant.
• Assess disposal tasks and compatibility with intended sharps containers.
• Include the needle in dose, usability and transport configurations.

Sharps-injury protection can also bring ISO 23908 into the standards plan. Usability evidence should address how users recognise activation and safe disposal states.

Mechanism capability needs margin across variation and life

The delivery mechanism must generate and control sufficient movement, force and energy across the full combination of product viscosity, needle resistance, container friction, tolerances, temperature, orientation and ageing—without creating unacceptable shock, noise, vibration or user forces.

Worst cases rarely reside in one nominal sample. Use tolerance analysis and risk-based configuration selection to identify combinations likely to challenge dose, delivery time, structural integrity and user interaction.

Part 4 extends the argument to electronics and software

ISO 11608-4 applies to needle-based injection systems containing electronics, with or without software. Electronic features can control delivery, detect states, provide feedback, record data, communicate or support ancillary functions.

• Identify which electronic functions are necessary for primary function or risk control.
• Define behaviour during battery depletion, interruption, reset, component fault and corrupted data.
• Control sensing accuracy, diagnostics, alarms, timing and state transitions.
• Assess electromagnetic disturbances where they could affect delivery or safety.
• Define electrical, thermal, battery and charging protection.
• Apply an appropriate software lifecycle and configuration controls.
• Assess wireless communication, cybersecurity and data integrity where connected functions matter.
• Distinguish therapy-critical operation from optional logging, reminders or companion services.

Use MTL-107 — Software Lifecycle, MTL-118 — Electrical Safety and Electromagnetic Compatibility and MTL-121 — Data, Connectivity and Interoperability where those functions apply.

Part 5 addresses automated functions and their sequence

ISO 11608-5 applies to automated functions in needle-based injection systems. Depending on the design, automation can include removal of a safety feature, activation, needle insertion, delivery, dwell, needle withdrawal and needle protection.

Automated steps create dependencies: one action can trigger several hidden transitions, and feedback may be the user’s only evidence that delivery has begun or completed. Define each state, transition, prevention of premature operation, fault response and indication.

Evaluate the automated sequence as a system. Passing isolated component tests cannot demonstrate correct interaction between functions.

Part 6 adds the realities of on-body delivery

ISO 11608-6 covers on-body delivery systems for single-patient use that provide a discrete bolus through a needle or soft cannula. Wear duration, adhesion, body movement, orientation and the user’s limited visibility of the delivery site make these systems different from hand-held injectors.

• Define skin preparation, placement, adhesion and removal across intended body sites.
• Evaluate cannula insertion, dislodgement, kinking, occlusion and leakage.
• Assess delivery across body orientation, movement, clothing and foreseeable contact.
• Define status, progress, completion and fault feedback when the site is not visible.
• Consider temperature, moisture, perspiration, impact and environmental exposure during wear.
• Address residual medicinal product, safe removal, sharps protection and disposal.
• Evaluate adhesive and patient-contact materials for biological safety.
• Consider interruption, reconnection or replacement instructions and clinical consequences.

Continuous-delivery pumps can sit outside Part 1 and Part 6 scope; determine applicability from the intended delivery profile rather than the product’s appearance.

Part 7 makes accessibility a system requirement

ISO 11608-7:2016 specifies particular requirements for systems claimed to be appropriate for people with visual impairment. It applies to devices intended for administration by patients or caregivers and extends beyond the device controls to safe and correct handling, labelling, packaging, instructions for use and training.

Accessibility should be designed into the complete user journey. Critical information and device states should not rely on vision alone when people with visual impairment are intended users. Audible, tactile and other non-visual cues can help users distinguish orientation, settings, readiness, initiation, progress, completion, faults and safe disposal.

• Define the intended user population and any accessibility claims explicitly.
• Identify safety-related tasks that users must complete independently.
• Make critical device states distinguishable without relying solely on colour, contrast or small visual details.
• Consider dose setting, counting, error recognition and recovery for users with limited or no vision.
• Make controls, components, ends and orientation distinguishable by appropriate tactile, audible or physical features.
• Address accessibility of packaging, labels, instructions, training and customer support.
• Evaluate the system with representative participants who have visual impairment.
• Consider compatibility with assistive technology and accessible electronic information.
• Document any reliance on a caregiver, training or environmental support as part of the use specification.
• Trace accessibility requirements and findings into usability engineering and risk management.

Use MTL-305 — IEC 62366-1 Usability Engineering and MTL-116 — Usability and Human Factors to integrate accessibility with the wider use-related risk process.

Conditioning must represent the claimed lifecycle

Performance should be evaluated after relevant environmental, mechanical and ageing exposures. The plan should connect each condition to transport, storage, use, shelf life and foreseeable handling.

Do not test every requirement on pristine samples if the claim applies after transport and shelf life. Conversely, avoid conditioning combinations that are not representative without explaining their conservative rationale.

Plan verification around claims, configurations and risks

The standards provide defined methods and performance expectations, but the manufacturer still needs a coherent verification strategy for the actual product family. Map every applicable requirement to configuration, conditioning, method, sample and acceptance criterion.

• Identify applicable ISO 11608 parts, amendments and external standards.
• Map product variants, drug strengths, doses, containers, needles, accessories and software.
• Select worst cases using technical rationale rather than convenience.
• Define representative production-equivalent samples and batch diversity.
• Control medicinal-product or surrogate properties and justify equivalence.
• Specify conditioning, test order, sample reuse and independence assumptions.
• Validate or qualify fixtures, automated methods and data-processing software.
• Capture raw data, invalid tests, deviations, anomalies and configuration identity.
• Link failures to investigation, corrective action and appropriate regression.

Use MTL-106 — Verification and Validation to organise protocols, objective evidence and conclusions.

Statistical design should match the decision

Sample numbers in a standard are not a substitute for understanding variation. Determine what population the samples represent, which sources of variation matter and what conclusion the analysis must support.

• Define the unit of analysis: dose, device, container, needle, batch or user interaction.
• Avoid treating repeated doses from one device as fully independent devices.
• Represent relevant component and manufacturing batches.
• Predefine exclusions, invalid-test rules, missing data and retest policy.
• Use appropriate confidence, tolerance or reliability methods for the requirement.
• Separate measurement uncertainty from product variation.
• Assess distribution shape, outliers, drift and position within acceptance limits.
• Justify pooling across variants, conditions or medicinal-product presentations.

A large number of repeated measurements from too few devices can create false confidence. The design should support inference about the manufactured product, not merely the tested specimens.

Transfer system-critical characteristics into production

ISO 11608 verification demonstrates a controlled design. Production and supplier controls must preserve the characteristics on which dose delivery, sterility, usability and safety depend.

Design verification methods may be unsuitable as high-volume release tests. Select production controls that detect or prevent meaningful variation while maintaining traceability to the verified design.

Assess changes across the combination—not in isolation

A change that appears local can alter system performance. New siliconisation can change stopper friction; a needle supplier can change flow resistance; a formulation or concentration can change viscosity; a spring or battery can alter delivery time; new firmware can alter state behaviour; new packaging can alter preconditioning.

• Define the baseline assessed configuration and affected claims.
• Evaluate impact on dose, delivery time, primary functions and risk controls.
• Assess drug stability, compatibility, sterility and container-closure integrity.
• Consider user workflow, labelling, training and usability evidence.
• Review environmental, transport, shelf-life and production implications.
• Determine analysis, focused regression, revalidation or wider retesting needed.
• Check regulatory reporting and combination-product change obligations.
• Update the standards matrix when editions or amendments change.

ISO 11608 evidence across the lifecycle

Build one connected evidence chain

A reviewer should be able to move from the intended therapy and applicable requirement to system design, representative conditioning and testing, statistical conclusion, production control and change assessment.

Use MTL-104 — Design Controls and Technical Documentation to keep the argument traceable rather than treating each laboratory report as a separate proof.

Common misconceptions

Practical implementation checklist

• Is the product within ISO 11608-1 scope, with exclusions explicitly considered?
• Are the applicable parts, 2026 amendments and related standards identified?
• Does the boundary include drug, container, fluid path, needle, device, accessories and user?
• Are primary functions, dose requirements and failure consequences explicit?
• Are drug properties and configuration ranges translated into design inputs?
• Does dose testing cover meaningful doses, conditions, life stages and combinations?
• Are container, fluid-path, needle and device interfaces jointly controlled?
• Are electronics, software, automated functions and on-body use addressed where applicable?
• Where visually impaired people are intended users, are Part 7 accessibility requirements and representative evaluation addressed?
• Does conditioning represent transport, storage, ageing and operational life?
• Are worst-case configurations and surrogate materials scientifically justified?
• Do samples and statistical methods support the intended product-level conclusion?
• Are measurement systems, fixtures and data processing suitable and controlled?
• Do production and supplier controls preserve critical characteristics?
• Are combination changes assessed across performance, usability, risk and regulatory evidence?